Tripti Gupta

Tripti Gupta

Auto-generated profile, based on publicly available information

Tripti Gupta

Department of Medicine, UC San Diego School of Medicine, University of California San Diego, California, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Progress in Cardiovascular Diseases
Verified
Journal Article
Closed access
GMGeorge Mcleod
George Mcleod
KSKelly Shum
Kelly Shum
TGTripti Gupta
Tripti Gupta
SCShourjo Chakravorty
Shourjo Chakravorty
SKSergey Kachur
Sergey Kachur
SSSangeeta B. Shah
Sangeeta B. Shah

16 December 2019 in Ochsner Journal
Verified
Journal Article
Open access
PDF file
TGTripti Gupta
Tripti Gupta
SKSelim R. Krim
Selim R. Krim
Background: With an aging population, the prevalence of heart failure continues to rise. The use of guideline-directed medical therapy and mechanical circulatory support devices has helped to improve outcomes, but cardiac transplantation remains the definitive treatment for end-stage heart failure. Methods: We provide an update on cardiac transplantation and review indications, contraindications, and important aspects of perioperative and postoperative management. We also highlight the current challenges faced by the transplant community. Results: Advances in surgical techniques and immunosuppression have increased survival rates posttransplant. However, the risk of rejection and adverse effects from chronic immunosuppression continue to affect long-term outcomes. Conclusion: Despite tremendous progress in the management of cardiac transplant patients, we have much opportunity to further optimize cardiac transplant waitlisting and improve posttransplant outcomes.

1 September 2018 in Progress in Cardiovascular Diseases
Verified
Journal Article
Closed access
KSKelly K. Shum
Kelly K. Shum
TGTripti Gupta
Tripti Gupta
MCMary M. Canobbio
Mary M. Canobbio
JDJennifer Durst
Jennifer Durst
SSSangeeta B. Shah
Sangeeta B. Shah

17 August 2021 in Vascular Medicine
Verified
Journal Article
Closed access
PDF file
TGTripti Gupta
Tripti Gupta
PMPatrick Manning
Patrick Manning
DKDhaval Kolte
Dhaval Kolte
KSKim G Smolderen
Kim G Smolderen
NSNancy Stone
Nancy Stone
JAJ Dawn Abbott
J Dawn Abbott

1 July 2019 in Current Opinion in Cardiology
Verified
Journal Article
Closed access
TGTripti Gupta
Tripti Gupta
TRTameem Rezan
Tameem Rezan
SKSelim R. Krim
Selim R. Krim
Hypertension (HTN) is one of the strongest risk factors for heart failure and is prevalent in up to 91% of patients with newly diagnosed heart failure. This article offers a practical approach to HTN in patients with heart failure. To date, no randomized trials comparing specific antihypertensive regimens have been conducted in the heart failure population. Management of heart failure with reduced ejection fraction patients with elevated blood pressure (BP) should include guideline-directed medical therapy [angiotensin-converting-enzyme inhibitors (ACEis), aldosterone receptor blockers, AT1 neprilysin-inhibitors, beta blockers and aldosterone blockers] titrated to maximal tolerated doses regardless of BP. Despite the lack of survival benefit current available data suggest the use of ACEis, aldosterone receptor blockers as first-line therapy for HTN in patients with heart failure with preserved ejection fraction. Management of HTN in heart failure patients should be based on left ventricular function. Recent findings suggest that AT1 neprilysin-inhibitors offer better BP control when compared with ACEi, or aldosterone receptor blockers and therefore should be used as first-line therapy in hypertensive patients with heart failure with reduced ejection fraction. Their role as antihypertensive agents in heart failure with preserved ejection fraction seems promising but remains under investigation.

4 June 2022 in Heliyon
Verified
Journal Article
Open access
NBNischit Baral
Nischit Baral
AVAnnabelle Santos Volgman
Annabelle Santos Volgman
TGTripti Gupta
Tripti Gupta
AKArvind Kunadi
Arvind Kunadi
MKMahin R. Khan
Mahin R. Khan
MTMelissa Tracy
Melissa Tracy
Infective endocarditis (IE) is a rare but serious complication following a Solid Organ Transplant (SOT). Due to the lack of sufficient studies, we aimed to compare in-hospital mortality and length of stay (LOS) of patients primarily admitted for IE (index or principal hospitalization) with history of SOT, including the subgroup of heart or lung transplant (HLT), to those without a history of SOT (non-SOT) or HLT (non-HLT). We used the 2016–2019 National Inpatient Sample, the largest all-payer inpatient hospital data from Healthcare Cost and Utilization Project (HCUP), including patients 18 years or older with IE, as a principal diagnosis for hospitalization. From 2016 to 2019, there were 56,330 principal or index hospitalizations for IE. Among them, 0.6 % (n = 327) were SOT recipients, 0.1% (n = 68) were HLT recipients, and 41.4% were females. The mean age was 51.9 ± 19.2 years. Compared to non-SOT controls, SOT recipients were older (mean age 59.3 vs. 51.8 years; P = 0.002) and had higher Charlson-comorbidity-index (CCI) of 3 or more (87.7% vs. 33.2%; p < 0.001). SOT status was not statistically significant for a higher or lower odds of in-hospital mortality (adjusted odds ratio (aOR) 0.7; 95% confidence interval (CI): 0.2, 2.4; p = 0.60) or increased or decreased LOS (coefficient: -0.1, 95% CI: -0.4, 0.1; p = 0.23) among index IE hospitalizations after controlling for age, sex, race, hospital-region, hospital-teaching status, income, insurance status, and CCI. HLT status was also not associated with higher or lower odds of in-hospital mortality (aOR 1.4; 95% CI: 0.2, 13.1; p = 0.77) or increased or decreased LOS (coefficient: -0.1, 95% CI: -0.3, 0.5; p = 0.59). From 2016 to 2019, the rate of index IE hospitalization trends from 37.8 to 41.4 per 100,000 overall hospitalizations (p = 0.001). We found the rate of index IE hospitalizations increasing with time. Among index IE hospitalizations, SOT, including a subgroup of HLT recipients, have similar in-hospital mortality and LOS compared to non-SOT or non-HLT groups. We need a larger sample size to comment on outcomes of IE hospitalizations with the HLT subgroup.